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Abstract 
Major improvements have been made in the treatment of myeloma. However, all patients, perhaps 
with some exceptions, eventually relapse, even after autologous stem cell transplantation (ASCT). 
In that setting, the combinations of new drugs, namely the IMiDs and the proteasome inhibitors 
along with steroids, give encouraging results in relapsed patients. The median progression-free 
survival (PFS) is 20 months with lenalidomide plus dexamethasone plus ixazomib and 26 months 
with lenalidomide plus dexamethasone plus carfilzomib. Monoclonal antibodies have emerged as an 
additional new treatment option. The antibody anti-SLAMF7, elotuzumab, in combination with 
lenalidomide plus dexamethasone gives a median PFS of 20 months. The antibody daratumumab, 
targeting CD38, alone has an outstanding activity in previously heavily treated patients. Its use in 
combination is ongoing. Transplantation remains a major treatment option. For patients who relapse 
at least 18 months from the initial ASCT, a second ASCT can be performed with an expected time 
to progression of 19 months from the time of transplantation. For patients relapsing earlier and/or 
with high-risk characteristics and who are still chemosensitive, with a suitable donor, an allogeneic 
transplantation can be considered. The optimal treatment combination and sequence remain to be 
determined. 
Keywords: Myeloma, relapse, proteasome inhibitors, immunomodulatory drugs, monoclonal 
antibodies, autologous stem cell transplantation, allogeneic stem cell transplantation 
Introduction 
Autologous stem cell transplantation (ASCT) is the standard treatment for younger newly diagnosed 
patients with multiple myeloma (MM). However, ultimately all patients will experience relapse 
following ASCT. The number of treatment options after relapse to an autograft is increasing.[1 
Oscio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in 
multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). 
Leukemia. 2014;28:525–542.[CrossRef], [PubMed], [Web of Science ®],2 Laubach J, Garderet L, 
Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the 
international myeloma working group. Leukemia. 2016;30:1005–1017.[CrossRef], [PubMed], 
[Web of Science ®]] One must first consider what type of relapse is occurring as this will affect 
future treatment strategies. Three parameters have a major role in the treatment decision: (1) The 
disease characteristics: is it high or standard risk? In this regard, the cytogenetic analysis has a 
prognostic impact as well as whether there is an extramedullary relapse. (2) The past treatment 
efficacy and toxicity and the duration of response after the autograft. (3) The patient characteristics: 
does he/she have comorbidities? and what is the patient’s choice? With the need for treatment 
established, the patient can be treated with a nontransplant approach or a transplant approach with 
either another autologous or/and an allogeneic transplantation.[3–5 Holstein SA, Richardson PG, 
Laubach JP, et al. Management of relapsed multiple myeloma after autologous stem cell transplant. 
Biol Blood Marrow Transplant. 2015;21:793–798. 
Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplant, European 
Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials 
Network and International Myeloma Working Group Consensus conference on salvage 
hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow 
Transplant. 2015;21:2039–2051. 
Bruno B, Auner HW, Gahrton G, et al. Stem cell transplantation in multiple myeloma and other 
plasma cell disorders (report from an EBMT preceptorship meeting). Leuk Lymphoma. 2016;6:1–
13.] 
The Chronic Malignancies Working Party of the European Society of Blood and Marrow 
Transplantation organized an Educational meeting in January 2016 in Hamburg/Germany 
addressing the issue of myeloma treatment relapse options following a previous autologous 
transplantation. This report summarized the options presented by the members of the faculty. 
Immunomodulatory drugs 
Immunomodulatory drugs (IMiDs) were the first new drugs to join standard chemotherapy to 
improve the treatment of myeloma. They have a dual mechanism of action, involving both a direct 
tumoricidal activity and a immunomodulation. The tumoricidal effect occurs through several 
mechanisms, including disruption of stromal support, induction of tumor suppressor genes and 
activation of caspases. The immunomodulatory effects includes T-cell and natural killer (NK)-cell 
activation, and increased expression of death effector molecules, which lead to enhanced immune 
cell function. There are currently three major IMiDs, namely thalidomide, lenalidomide 
(Revlimid
®
) and pomalidomide (Imnovid
®
 in Europe and Pomalyst
®
 in the United States). 
In 1999, the Arkansas group reported the efficacy of single agent thalidomide in the relapse 
setting.[6 Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory 
multiple myeloma. N Engl J Med. 1999;341:1565–1571.[CrossRef], [PubMed], [Web of Science 
®]] The overall response rate (ORR) was 32% with a two-year PFS of 20% and overall survival 
(OS) of 48%. At that time, the thalidomide dose range was high from 200 mg to 800 mg per day 
with a high toxicity, especially peripheral neuropathy. Currently, thalidomide is rarely given above 
200 mg per day which is usually well tolerated. If combined to steroid, namely dexamethasone, the 
ORR increases to 46%.[7 von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review 
of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or 
refractory multiple myeloma. Eur J Haematol. 2008;81:247–252.[CrossRef], [PubMed], [Web of 
Science ®]] The second-generation IMiD, lenalidomide, was reported in two pivotal studies 
published in 2007 with similar results.[8 Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide 
plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–
2132.[CrossRef], [PubMed], [Web of Science ®],9 Weber DM, Chen C, Niesvizky R, et al. 
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 
2007;357:2133–2142.[CrossRef], [PubMed], [Web of Science ®]] Lenalidomide plus 
dexamethasone induces a partial response or better of 60% with a time to progression of 11 months. 
In a phase-I study, pomalidomide was first tested in patients refractory to both proteasome 
inhibitors and immunomodulatory drugs. In combination with dexamethasone, the ORR was 
34%.[10 Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and 
efficacy in patients with refractory multiple myeloma who have received lenalidomide and 
bortezomib. Blood. 2013;121:1961–1967.[CrossRef], [PubMed], [Web of Science ®]] The optimal 
dose was established of 4 mg per day, for 21 days followed by 7 days off therapy.[11 Leleu X, Attal 
M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in 
bortezomib and lenalidomide-refractory multiple myeloma: intergroupe francophone du myélome 
2009-02. Blood. 2013;121:1968–1975.[CrossRef], [PubMed], [Web of Science ®]] Pomalidomide 
plus weekly low-dose dexamethasone was then shown to be superior to dexamethasone alone. In 
this trial, patients had received a median of 5 (2–14) lines of treatment, including 70% with a prior 
ASCT. The PFS was 4 months versus 1.9 months and the OS was 12 months versus 8 months in 
favor of pomalidomide plus dexamethasone.[12 San Miguel J, Weisel K, Moreau P, et al. 
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients 
with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. 
Lancet Oncol. 2013;14:1055–1066.[CrossRef], [PubMed], [Web of Science ®]] In 2015, the IFM 
reported a potential efficacy of pomalidomide for patients harboring the 17 p deletion.[13 Leleu X, 
Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with 
deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015;125:1411–
1417.[CrossRef], [PubMed], [Web of Science ®]] 
These three drugs are all approved by the health authorities in the relapse setting in Europe except 
pomalidomide which is not currently funded in the United Kingdom. Pomalidomide is restricted to 
patients who relapse/progress after having received at least two prior therapies (including 
lenalidomide and bortezomib) and have disease progression on/or within 60 days of completion of 
the last therapy.[14 Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement 
on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 
2014;28:1573–1585.[CrossRef], [PubMed], [Web of Science ®]] 
Proteasome inhibitors 
Proteasome inhibitors block the degradation of intracellular proteins in the ubiquitin–proteasome 
system and trigger proteotoxic stress preferentially in multiple myeloma cells.[15 Auner HW, Cenci 
S. Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. 
Br J Haematol. 2015;168:14–25.[CrossRef], [PubMed], [Web of Science ®],16 Moreau P, 
Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 
2012;120:947–959.[CrossRef], [PubMed], [Web of Science ®]] The first in this class was 
bortezomib (Velcade
®
, a boronic acid-based proteasome inhibitor) followed by carfilzomib 
(Kyprolis
®
, an epoxyketone) and more recently the orally bioavailable boronic acid-based ixazomib 
(Ninlaro
®
). 
In a pivotal phase-II study, bortezomib monotherapy (plus dexamethasone in patients with a 
suboptimal response) administered to 202 patients with relapsed or refractory (RR) MM was 
associated with an ORR of 35%. The median duration of response (DOR) was 12 months, and 
median OS was 16 months.[17 Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of 
bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617.[CrossRef], 
[PubMed], [Web of Science ®]] The phase-III APEX study confirmed the efficacy of single-agent 
bortezomib in RR MM.[18 Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-
dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–
2498.[CrossRef], [PubMed], [Web of Science ®]] The study included 669 RR MM patients with a 
median of two prior therapies who were randomized to intravenous (IV) bortezomib or intensive 
high-dose dexamethasone. Bortezomib was superior in terms of ORR (38% vs. 18%, p < .001), 
median TTP (6.2 vs. 3.5 months, p < .001) and one-year OS rate (80% vs. 66%, p = .003). 
Bortezomib activity was independent of chromosomal abnormalities such as del(13) and t(4;14).[19 
Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response 
rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 
2007;21:164–168.[CrossRef], [PubMed], [Web of Science ®]] Major bortezomib-related toxicities 
included peripheral neuropathy, gastrointestinal symptoms, fatigue, thrombocytopenia, neutropenia, 
and herpes zoster reactivation. The addition of dexamethasone to IV bortezomib improved rates of 
response without prohibitive toxicity.[20 Jagannath S, Richardson PG, Barlogie B, et al. 
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or 
refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 
2006;91:929–934.[PubMed], [Web of Science ®]] 
In contrast to bortezomib, carfilzomib is an irreversible proteasome inhibitor.[21 Demo SD, Kirk 
CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. 
Cancer Res. 2007;67:6383–6391.[CrossRef], [PubMed], [Web of Science ®]] Two parallel phase-II 
studies, PX-171-003-A1 and PX-171-004, evaluated carfilzomib in patients with RR MM. In the 
open-label, single-arm phase-II PX-171-003-A1 study, patients received carfilzomib 20 mg/m2 IV 
twice weekly for 3 out of 4 weeks in cycle 1, then 27 mg/m2 in a similar schedule for up to 12 
cycles. Patients had a median of 5 prior lines of therapy including 75% with a prior ASCT and 80% 
were refractory to or intolerant of both bortezomib and lenalidomide. ORR was 24% with median 
DOR of 7.8 months and a median OS of 15.6 months. Common adverse events included fatigue, 
anemia, nausea, and thrombocytopenia. Twelve percent experienced peripheral neuropathy, 
primarily grades 1 to 2. Some significant cardiopulmonary toxicity as well as renal dysfunction was 
also encountered.[22 Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent 
carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 
2012;120:2817–2825.[CrossRef], [PubMed], [Web of Science ®]] 
In the PX-171-004 study, carfilzomib with low-dose dexamethasone premedication was given to 
two cohorts of bortezomib-naïve RR MM patients. Patients in cohort 1 received IV carfilzomib 
20 mg/m2 for all treatment cycles, while those in cohort 2 received 20 mg/m2 in cycle 1 and 
27 mg/m2 in subsequent cycles. The ORR was 59% and 64% in cohorts 1 and 2, respectively. 
Median DOR was 13 months and not reached, and median TTP was 8 months and not reached, 
respectively.[23 Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-
004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory 
multiple myeloma. Blood. 2012;119:5661–5670.[CrossRef], [PubMed], [Web of Science ®]] 
The ENDEAVOR study [24 Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and 
dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory 
multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicentre study. Lancet 
Oncol. 2016;17:27–38.[CrossRef], [PubMed], [Web of Science ®]] compared bortezomib–
dexamethasone with carfilzomib–dexamethasone in 922 patients with relapsed/refractory myeloma, 
of whom 58% had previously undergone an ASCT. Patients received treatment with carfilzomib 
(20 mg/m2 on days 1 and 2 of cycle 1; 56 mg/m2 thereafter) or bortezomib (1.3 mg/m2; intravenous 
bolus or subcutaneous injection). Median progression-free survival was superior in the carfilzomib 
group compared to the bortezomib group (18.7 months vs. 9.4 months). Serious adverse events were 
reported in 48% of the patients in the carfilzomib group and in 36% of the patients in the 
bortezomib group. Importantly, the toxicity profiles differed between the two proteasome inhibitor 
groups, with cardiopulmonary events occurring more frequently in the patients treated with 
carfilzomib, but with higher neuropathy rates in the bortezomib group. Discontinuation rates were 
comparable in the two groups. 
Recent phase-I and phase-II trials of the orally bioavailable proteasome inhibitor ixazomib showed 
that the drug has promising single-agent activity in relapsed myeloma along with a favorable 
toxicity profile and that addition of dexamethasone enhances the response rates.[25–27 Kumar SK, 
LaPlant B, Roy V, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not 
refractory to bortezomib. Blood Cancer J. 2015;5:e338. 
Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome 
inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014;124:1038–1046. 
Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the 
investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 
2014;124:1047–1055.] The findings suggest an important role for this two-drug combination and 
have informed further clinical development (also refer to the following section). 
Triplet combinations incorporating an IMiDs and a proteasome inhibitor 
IMiDs are now combined with other very active drugs and especially with the proteasome inhibitors 
and the monoclonal antibodies (Table 1). The most active three drug combinations are currently 
bortezomib plus thalidomide and dexamethasone (VTD), lenalidomide (Revlimid
®
) plus 
dexamethasone with either bortezomib (RVD or VRD), carfilzomib (CRD) or ixazomib or with the 
monoclonal antibodies elotuzumab or daratumumab. HDAC inhibitors in different combinations are 
also under investigation. 
Table 1. Pivotal randomized phase-III clinical trials with triple combinations in the relapse 
setting. 
 
Btz: bortezomib; Carfil: suppress the z; CR/nCR: complete response/near complete response; Dex: 
dexamethasone; Elo: elotuzumab; Len: lenalidomide; mo: median months; NA: not available; ORR: overall 
response rate; OS: overall survival; Pano: panobinostat; PFS: progression-free survival; PR: partial 
remission; TD: thalidomide dexamethasone; TTP: time to progression; VGPR: very good partial remission; 
VTD: velcade thalidomide dexamethasone. 
 
The superiority of a triplet combination over a doublet in the relapse setting post ASCT was first 
demonstrated in 2012. In a phase-III study that was limited to patients with a first relapse or 
progression after at least one prior ASCT,[29 Garderet L, Iacobelli S, Moreau P, et al. Superiority 
of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of 
thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after 
autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the 
Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J 
Clin Oncol. 2012;30:2475–2482.[CrossRef], [PubMed], [Web of Science ®]] the IFM and EBMT 
compared the efficacy and safety of a PI-containing triple combination (bortezomib–thalidomide–
dexamethasone [VTD]) with that of thalidomide–dexamethasone (TD). VTD resulted in a 
significantly longer median time to progression (19.5 vs. 13.8 months), a higher complete response 
plus near-complete response rate (45% vs. 21%), and a longer median duration of response (17.9 vs. 
13.4 months) compared to TD. However, peripheral neuropathy, infection, and thrombocytopenia 
were significantly more frequent with VTD. 
In a phase-II study of bortezomib and dexamethasone in combination with lenalidomide in patients 
with RR MM, of whom 36% had received a prior ASCT, median progression-free and overall 
survival were 9.5 and 30 months, respectively.[30 Richardson PG, Xie W, Jagannath S, et al. A 
phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and 
relapsed/refractory myeloma. Blood. 2014;123:1461–1469.[CrossRef], [PubMed], [Web of Science 
®]] In this study, the triple combination was considered tolerable with a very low rate of grade 3/4 
neuropathies (3%). 
The ASPIRE investigators compared carfilzomib–lenalidomide–dexamethasone to lenalidomide–
dexamethasone in relapsed/refractory myeloma patients, of whom 56% had previously undergone 
an ASCT.[31 Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and 
dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.[CrossRef], 
[PubMed], [Web of Science ®]] Median progression-free survival was significantly improved with 
carfilzomib compared with the control group (26.3 months vs. 17.6 months). A complete response 
or better was observed in 31.8% and 9.3% of patients in the respective groups. Adverse events of 
grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control 
groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. 
Importantly, patients treated with the three-drug regimen reported superior health-related quality of 
life and there was a trend toward improved overall survival in the carfilzomib group. 
The phase-III TOURMALINE-MM1 study (NCT01564537) results reported at the 2015 Annual 
Meeting of the American Society of Hematology showed that addition of the oral proteasome 
inhibitor ixazomib to lenalidomide–dexamethasone improved median progression-free survival 
from 14.7 to 20.6 months and VGPR + CR rates from 39% to 48.1%, at comparable adverse event 
rates in RR MM patients that were not refractory to lenalidomide or proteasome inhibitor-based 
therapy.[32 Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide and dexamethasone 
for relapsed multiple myeloma. N Engl J Med. 2016;374:1621–1634.[CrossRef], [PubMed], [Web 
of Science ®]] 
While other drug combinations including proteasome inhibitors (such as those including 
cyclophosphamide or adriamycin, both with dexamethasone) have been reported or are still being 
investigated, and with the limitations of cross-trial comparisons, the triple combination of 
carfilzomib–lenalidomide–dexamethasone as investigated in the ASPIRE trial should probably be 
considered as the current most effective proteasome inhibitor-based regimens in RR MM. 
For pomalidomide, the most promising combinations are those with cyclophosphamide or 
bortezomib. In a phase-II trial involving patients with RR MM who were lenalidomide refractory 
and received at least two prior therapies, patients received pomalidomide 4 mg days 1–21 plus 
weekly dexamethasone 40 mg in a 28-day cycle, with or without oral cyclophosphamide 400 mg 
days 1, 8, and 15. The triple combination pomalidomide–cyclophosphamide–dex was superior with 
a rate of PR or better of 65%, a PFS of 9.2 months and an OS of 16.4 months.[33 Baz R, Martin 
TG, Lin HY, et al. Randomized multicenter phase II study of pomalidomide, cyclophosphamide, 
and dexamethasone in relapsed refractory myeloma. Blood. 2016;127:2561–2568.[CrossRef], 
[PubMed], [Web of Science ®]] A phase-III study is ongoing comparing pomalidomide 
dexamethasone with or without bortezomib.[34 Richardson PG, Craig Hofmeister C, Raje NS, et al. 
A phase 1, multicenter study of pomalidomide, bortezomib, and low-dose dexamethasone in 
patients with proteasome inhibitor exposed and lenalidomide-refractory myeloma (Trial MM-005). 
ASH annual meeting, 2015. Abst 3036.] 
Monoclonal antibodies 
The use of monoclonal antibodies (mAbs) are emerging as new successful therapeutic strategies in 
multiple myeloma. Of these, CD38 (daratumumab, isatuximab, MOR202) and SLAMF7 
(Elotuzumab) targeting mAbs are most advanced in clinical development.[35–38 Lokhorst HM, 
Plesner T. Laubach, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N 
Engl J Med. 2015;373:1207–1219. 
Martin K, Strickland S, Glenn M, et al. A phase I trial of SAR650984, a CD38 monoclonal 
antibody, in relapsed or refractory multiple myeloma. J Clin Oncol. 2014;32:8532. 
Raab S, Goldschmidt H. Agis, et al. A phase 1/2a study of the human anti-CD38 antibody MOR202 
(MOR03087) in relapsed or refractory multiple myeloma. Haematologica. 2015;100:S789. 
Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple 
myeloma. N Engl J Med. 2015;373:621–631.] Daratumumab and isatuximab have marked single-
agent activity in extensively pretreated MM and show enhanced efficacy combined with other 
agents, especially with IMIDS (Table 2). Elotuzumab has no single-agent activity in advanced MM; 
however, significantly improved progression-free survival was shown when elotuzumab was 
combined with lenalidomide–dexamethasone or bortezomib–dexamethasone (Table 1). 
Table 2. Anti-CD38 Monoclonal antibodies phase-I and phase-II studies. 
 
CR/nCR: complete response/near complete response; Dara: daratumumab; Dex: dexamethasone; IRR: 
infusion-related reaction; Len: lenalidomide; mo: median months; NA: not available; OS: overall survival; 
PFS: progression-free survival; Pom: pomalidomide; PR: partial remission; VGPR: very good partial 
remission. 
Various mechanisms explain the workings of these antibodies, which include direct induction of 
apoptosis, complement dependent cytotoxicity (CDC), antibody dependent cellular cytotoxicity 
(ADCC) or antibody-dependent cellular phagocytosis (ADCP).[39–41 van de Donk NW, Kamps S, 
Mutis T, et al. Monoclonal antibody-based therapy as a new treatment strategy in multiple 
myeloma. Leukemia. 2012;26:199–213. 
Balasa B, Yun R, Belmar NA, et al. Elotuzumab enhances natural killer cell activation and 
myeloma cell killing through interleukin-2 and TNF-alpha pathways. Cancer Immunol Immunother. 
2015;64:61–73. 
Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the 
anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. 
MAbs. 2015;7:311–321.] 
CD38 
CD38 is a 46 kDa type-II transmembrane glycoprotein.[42 Malavasi F, Funaro A, Roggero S, et al. 
Human CD38: a glycoprotein in search of a function. Immunol Today 1994;15:95–96.[CrossRef], 
[PubMed],43 de Weers M, Tai YT. van der Veer, et al. Daratumumab, a novel therapeutic human 
CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J 
Immunol. 2011;186:1840–1848.[CrossRef], [PubMed], [Web of Science ®]] Lymphoid as well as 
myeloid but also nonhematopoietic tissues express CD38 on their surface.[44 Deaglio S, Mehta K, 
Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leukemia Res. 
2001;25:1–12.[CrossRef], [PubMed], [Web of Science ®]] Virtually all MM cells express high 
levels of CD38, similar to normal plasma cells.[43 de Weers M, Tai YT. van der Veer, et al. 
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple 
myeloma and other hematological tumors. J Immunol. 2011;186:1840–1848.[CrossRef], [PubMed], 
[Web of Science ®],44 Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of 
enzymes and receptors. Leukemia Res. 2001;25:1–12.[CrossRef], [PubMed], [Web of Science ®]] 
CD 38 is also expressed on 80% of resting NK cells and monocytes (at lower levels) and 
interestingly also on activated T cells and subsets of various immune effector cells including 
dendritic cells, regulatory T cells and myeloid-derived suppressor cells.[45 Krejcik J, Casneuf T, 
Nijhof I, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, 
and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–394.[CrossRef], [PubMed]] 
Of note, CD38 is also expressed in lungs leading to common infusion reactions, and red blood cells 
leading to inability to cross match blood in patients in need of transfusions. 
Daratumumab 
Daratumumab is a human IgG1 (κ subclass) antibody blocking the CD38 molecule. It binds 
specifically to amino acids 233–246 and 267–280 of CD38 that enables an optimal interaction 
between the Fc portion of the antibody and complement or antibody dependent cytotoxic cells.[43 
de Weers M, Tai YT. van der Veer, et al. Daratumumab, a novel therapeutic human CD38 
monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J 
Immunol. 2011;186:1840–1848.[CrossRef], [PubMed], [Web of Science ®]] 
In a phase-I–II clinical trial (GEN501 study), daratumumab as a single agent was evaluated in 
relapsed MM or MM refractory to two or more previous lines of therapy, including Auto-SCT in 
the majority of patients.[35 Lokhorst HM, Plesner T. Laubach, et al. Targeting CD38 with 
daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–1219.[CrossRef], 
[PubMed], [Web of Science ®]] Part 1 of the study had a dose escalation design and in part 2 
different dosing schedules were devised. In part 1, the maximum tolerated dose was not reached. In 
16 mg/kg cohort of part 2, the overall response rate (ORR) was 36% with 15 patients showing at 
least PR, including two patients with VGPR and two with CR. ORR were lower in the 8 mg/kg 
cohort (10%). Median PFS in the 16 mg/kg groups was 5.6 months, while 65% of responding 
patients had not progressed until 12 months of follow-up. Daratumumab infusion appeared to be 
safe. In part 2 of the GEN501 study, 48% of patients experienced infusion-related reactions which 
were mild (all grades, 71%; grade 3, 1%), mainly restricted to the first infusion. 
The encouraging results of the GEN501 were corroborated by Lonial et al. in the SIRIUS (MMY 
2002) trial which enrolled 106 patients – the majority refractory to bortezomib or lenalidomide and 
had received a median of 5 prior lines of treatment, including 80% with a prior ASCT. Patients 
treated with 16 mg/kg daratumumab, featured a PR in 29% with sCR in 3% of the patients. Median 
PFS was 3.7 months with a one year OS of 65%. 21% of those patients that were refractory to 
bortezomib, carfilzomib, pomalidomide, or lenalidomide showed PRs or better.[46 Lonial S, Weiss 
BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple 
myeloma (SIRIUS): an open-label, randomized, phase 2 trial. Lancet. 2016;387:1551–
1560.[CrossRef], [PubMed], [Web of Science ®]] 
Usmani et al. presented at ASH 2015 the combined analysis of 146 patients treated with 16 mg/kg 
daratumumab of the GEN501 and SIRIUS trial.[47 Usmani A, Weiss B, Bahlis NJ, et al. Clinical 
efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory 
multiple myeloma. Blood. 2015;126:29.] The ORR was 31%, duration of response was 7.6 months 
and 46% of responders remained progression free at 1 year after a median follow-up of 9.3 month. 
In this combined analysis after a median follow-up of 14.8 months, estimated OS was 19.9 months. 
Importantly, ORR was similar irrespective of ISS, number of prior therapies and refractory status. 
Isatuximab and MOR 202 
Isatuximab has been evaluated in relapsed/refractory MM patients in a dose escalation study. With 
dosing up to 20 mg/kg the MTD was not reached and in 18 heavily pretreated patients a dose of 
10 mg isatuximab induced at least PR in 33% including CR in 11%.[36 Martin K, Strickland S, 
Glenn M, et al. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or 
refractory multiple myeloma. J Clin Oncol. 2014;32:8532.[CrossRef]] In an ongoing phase-I dose-
escalation study, MOR202 is well tolerated and the MTD has not been reached. Some long-lasting 
tumor control has been observed.[37 Raab S, Goldschmidt H. Agis, et al. A phase 1/2a study of the 
human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma. 
Haematologica. 2015;100:S789.] 
Combination therapies including monoclonal antibodies 
IMIDs 
The rationale for combining IMIDS with elotuzumab and CD38 targeting mAbs comes from 
preclinical studies showing the activation of the effector cells of ADCC by lenalidomide.[48–50 
Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity 
against myeloma via CS1 ligation: evidence for augmented NK cell function complementing 
ADCC. Cancer Immunol Immunother. 2013;62:1841–1849. 
van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: 
enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 
monoclonal antibody daratumumab. Haematologica. 2011;96:284–290. 
Endell J, Boxhammer R, Wurzenberger C, et al. The activity of MOR202, a fully human anti-CD38 
antibody, is complemented by ADCP and is synergistically enhanced by lenalidomide in vitro and 
in vivo. Blood. 2012;120:4018.] 
In the randomized phase-III trial (ELOQUENT-2) in RR MM (1–3 prior therapies), elotuzumab 
(10 mg/kg) combined with lenalidomide–dexamethasone improved median PFS by 4.5 months 
(14.9 to 19.4 months), as compared to lenalidomide–dexamethasone. This PFS benefit was 
independent of age (patients 65 years of age or older), presence of del(17p), or creatinine clearance 
of less than 60 ml/min. Also the overall response rate was higher in the elotuzumab group compared 
to the control group (79% vs. 66%).[38 Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab 
therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.[CrossRef], 
[PubMed], [Web of Science ®]] 
Phase–I–II trials of daratumumab and isatuximab with lenalidomide–dexamethasone in RR MM 
showed impressively high response rates that improved over time. Interestingly, response (≥PR: 
48%) was also achieved in lenalidomide-refractory patients.[36 Martin K, Strickland S, Glenn M, 
et al. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory 
multiple myeloma. J Clin Oncol. 2014;32:8532.[CrossRef],51 Plesner T, Arkenau H, Gimsing P, 
et al. Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed 
or relapsed and refractory multiple myeloma: updated results of a phase 1/2 study (GEN503). 
Blood. 2015;126:507.] Pomalidomide combined with daratumumab induced a high overall response 
rate in RR MM patients including a ≥PR: 67% in double refractory patients.[52 Chari A, Lonial S, 
Suvannasankha A, et al. Open-label, multicenter, phase 1b study of daratumumab in combination 
with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed 
or relapsed and refractory multiple myeloma. Blood. 2015;126:508.[CrossRef], [PubMed], [Web of 
Science ®]] 
Immune-modulating effects by daratumumab: contributing to efficacy? 
Immune monitoring of patients included in GEN501 and SIRIUS trials showed robust immune 
effects (T cell increases, increased CD8+/CD4 + ratios, increased antiviral responses, and increased 
T cell clonality) which were surprising to observe in heavily pretreated, relapsed and refractory 
patients. Improved clinical responses were associated with changes in these parameters. 
Additionally, a subpopulation of regulatory T cells expressing high CD38 levels and known to be 
extremely immune suppressive were completely eliminated by daratumumab treatment. These data 
suggest a previously unknown immune modulatory role of daratumumab that may contribute to its 
efficacy, and a potential role for CD38 immune-targeted therapies.[45 Krejcik J, Casneuf T, Nijhof 
I, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and 
skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–394.[CrossRef], [PubMed]] 
Autologous stem cell transplantation 
To date, multiple reports of salvage autologous stem cell transplantation (sASCT) have been 
published, though they are primarily retrospective single center or registry-based studies [53–55 
Lemieux E, Hulin C, Caillot D, et al. Autologous stem cell transplantation: an effective salvage 
therapy in multiple myeloma. Biol Blood Marrow Transplant. 2013;19:445–449. 
Jimenez-Zepeda VH, Mikhael J, Winter A, et al. Second autologous stem cell transplantation as 
salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood 
Marrow Transplant. 2012;18:773–779. 
Grovdal M, Nahi H, Gahrton G, et al. Autologous stem cell transplantation versus novel drugs or 
conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. 
Bone Marrow Transplant. 2015;50:808–812.] (Table 3). Nonetheless, these studies highlighted the 
clinical utility and feasibility of sASCT, primarily where there is clear evidence of chemo-sensitive 
disease at relapse and under-pinned the prognostic impact of remission duration after first 
ASCT.[56 Kobayashi T, Kuroda J, Fuchida S, et al. The response to second-line induction with 
bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose 
chemotherapy with autologous stem cell transplantation for multiple myeloma. Intern Med. 
2013;52:961–968.[CrossRef], [PubMed], [Web of Science ®]] Most reports identified that the 
number of prior lines of prior therapy had a significant impact on outcomes suggestive of the most 
appropriate timing of sASCT.[57 Fenk R, Liese V, Neubauer F, et al. Predictive factors for 
successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous 
blood stem cell transplantation. Leuk Lymphoma. 2011;52:1455–1462.[Taylor & Francis Online], 
[Web of Science ®]] There has been however no data to direct clinicians in the timing of sASCT, 
that is, whether at biochemical or symptomatic relapse. In the EBMT database, since 1995, 
38,741 MM patients were reported to be in first relapse post-ASCT; however, most patients (83%) 
did not undergo a sASCT. When examined in a temporal setting, though sASCT was performed in 
4443 patients, there has been a constant increase in the sASCT year on year to more than 500 
patients per year since 2012 (Figure 1). 
 
  
Figure 1. Since 1995, evolution of autologous and allogeneic stem cell transplantation performed to 
treat relapse occurring after an initial autologous transplantation in Europe (EBMT registry). 
Table 3. Autologous and allogeneic stem cell transplantation studies in the relapse setting 
postautograft. 
 
 
Auto: autologous stem cell transplantation; Allo: allogeneic stem cell transplantation; CR/nCR: complete 
response/near complete response; mo: median months; NA: not available; NRM: nonrelapse mortality; OS: 
overall survival; PFS: progression-free survival; Pro: prospective; PR: partial remission; Retro: retrospective; 
RR: relapse rate; VGPR: very good partial remission. 
The first prospective randomized trial studying sASCT versus nontransplant consolidation (NTC) 
after first relapse and reinduction with a bortezomib-containing regimen has been reported by Cook 
et al.[58 Cook G, Williams C, Brown JM, et al. High-dose chemotherapy plus autologous stem-cell 
transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous 
autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomized, 
open-label, phase 3 trial. Lancet Oncol. 2014;15:874–885.[CrossRef], [PubMed], [Web of Science 
®]] This multicenter, randomized, open-label, phase-III study recruited patients with relapsed 
myeloma after a previous ASCT, reinducing disease control using a bortezomib-based regimen. 
Chemosensitive patients were randomly assigned (1:1), to sASCT or NTC consisting of oral 
cyclophosphamide (400 mg/m2 per week for 12 weeks). This trial showed a clear advantage in 
terms of time to progression, (19 vs. 11 months; p  < .0001) for sASCT compared to NTC. Now, 
with extended follow-up and poststudy relapse management details, there is evidence of a clear 
advantage in the PFS2 postdisease progression in the sASCT versus NTC cohort, despite the use of 
sASCT at on-protocol progression in a cohort of the NTC patients, as presented at ASH 2015. 
Furthermore, with a median follow-up which is 52 months, the median survival was superior in the 
sASCT compared with NTC cohorts (67 vs. 52 months; Log Rank p = .022). A reduced hazard of 
death in the sASCT group compared to NTC (HR = 0.56, 95%CI: [0.35, 0.90], p = .0169) was 
evident with CR/sCR to re-induction therapy (HR 0.14, p = .032), β2M level <3.5 mg/L (HR 0.35, 
p = .039) and the absence of high-risk iFISH (HR 0.36, p  = .007) associated with improved OS in 
favor of sASCT (manuscript in preparation). To date, this advantage in postprogression 
management and survivorship is not at the expense of an increased risk of second primary 
malignancies. It should however be mentioned that, nowadays, single-agent cyclophosphamide 
control arm is not a standard consolidation method for RRMM. 
This study, incorporated into the international relapsed myeloma guidelines, highlights several 
issues that need to be addressed prospectively. Though offering a dataset on which to base clinical 
decision making, the role of sASCT in the setting of IMiD or combined IMiD and PI usage remains 
to be clarified. Furthermore, the role of post-sASCT consolidation and maintenance has not been 
addressed. Both these issues will be addressed in the up and coming UKMRA Myeloma XII study 
(http://medhealth.leeds.ac.uk/info/410/haematological_oncology/1760/haematological_oncology) 
due to commence recruitment in Q2 of 2016. UKMRA Myeloma XII study aims, firstly, to 
determine what the impact on depth of response will be when sASCT conditioning is augmented by 
the addition of a proteasome inhibitor and, secondly, what will the influence on durability of 
response be with post-sASCT consolidation and maintenance therapy. In this study, induction 
treatment will use an Ixazomib-containing induction regimen 
(ixazomib/thalidomide/dexamethasone; ITD), which will build on the proven efficacy of PI/IMiD 
combinations. Furthermore, following the sASCT randomization comparing a conventional and an 
augmented transplant schema, an ixazomib-containing consolidation and maintenance strategy will 
be tested. Incorporated into this study is a comprehensive assessment to define the MRD
negative
 rate 
postreinduction, post-sASCT and conversion after ITD consolidation. 
The last issue that needs addressing is that of availability of sufficient PBSC for a sASCT. For 
many patients, it was not possible to collect enough hematopoietic stem cells or, for logistical 
reason enough stem cells were not collected and stored, that would support two transplants. Until 
recently there has been no data to indicate if re-mobilization after a prior ASCT is feasible. The 
myeloma X study has shown that PBSC can be remobilized successful in 55–60% of patients.[59 
Parrish C, Morris CT, Williams CD, et al. Stem cell harvesting after bortezomib-based re-induction 
for myeloma relapsing after autologous transplant: results from the BSBMT/UKMF myeloma X 
(Intensive) trial. Biol Blood Marrow Transplant. 2016;22:1009–1016.[CrossRef], [PubMed], [Web 
of Science ®]] There is an outstanding question, though, about whether such remobilized cells have 
any evidence of the replicative stresses induced by a previous transplant, either functionally or 
genomically. Myeloma X has not provided any evidence on this subject and no such data exists in 
the human system but, ongoing research will hopefully answer this issue in time. 
Thus, with long-term follow-up analysis, a sASCT offers both a disease control durability and a 
survival advantage when compared to a NTC, after bortezomib-based reinduction therapy in 
patients with MM relapsing after a prior ASCT. These data are key for patient-centered clinical 
decision making.[4 Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow 
Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant 
Clinical Trials Network and International Myeloma Working Group Consensus conference on 
salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood 
Marrow Transplant. 2015;21:2039–2051.[CrossRef], [PubMed], [Web of Science ®]] 
Allogeneic stem cell transplantation 
In myeloma, allogeneic stem cell transplantation is mostly performed in the relapse setting. The 
EBMT data registry shows that the numbers are still increasing over the years (Figure 1). Most 
reports on allografting as rescue strategy after a previous autograft have been single-center or 
retrospective registry analyses.[4 Giralt S, Garderet L, Durie B, et al. American Society of Blood 
and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and 
Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus 
conference on salvage hematopoietic cell transplantation in patients with relapsed multiple 
myeloma. Biol Blood Marrow Transplant. 2015;21:2039–2051.[CrossRef], [PubMed], [Web of 
Science ®],60 Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group 
consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple 
myeloma. J Clin Oncol. 2010;28:4521–4530.[CrossRef], [PubMed], [Web of Science ®],61 
Festuccia M, Martino M, Ferrando F, et al. Allogeneic stem cell transplantation in multiple 
myeloma: immunotherapy and new drugs. Expert Opin Biol Ther. 2015;15:857–872.[Taylor & 
Francis Online], [Web of Science ®]] Some retrospective studies have compared allogeneic to 
autologous stem cell transplantation.[62–66 Freytes CO, Vesole DH, LeRademacher L, et al. 
Second transplants for multiple myeloma relapsing after a previous autotransplant—reduced-
intensity allogeneic vs autologous transplantation. Bone Marrow Transplant. 2014;49:416–421. 
De Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as 
salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant. 2008;41:953–960. 
Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple 
myeloma refractory to or relapsing after a first-line autograft. Bone Marrow Transplant. 
1998;21:887–892. 
Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after 
the failure of first autograft in patients with multiple myeloma. Cancer. 2006;106:1084–1089. 
Wirk B, Byrne M, Dai Y, et al. Outcomes of salvage autologous versus allogeneic hematopoietic 
cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell 
transplantation. J Clin Med Res. 2013;5:174–184.] Overall, these studies showed the feasibility of 
allografting in relapsed multiple myeloma even though they included heterogeneous patient groups, 
differences in conditioning regimens and supportive care. Of note, Patriarca et al. reported an 
interesting study based on the availability of a suitable donor either related or unrelated in patients 
who relapsed after a first-line autograft.[67 Patriarca F, Einsele H, Spina F, et al. Allogeneic stem 
cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study 
based on donor availability. Biol Blood Marrow Transplant. 2012;18:617–626.[CrossRef], 
[PubMed], [Web of Science ®],68 Patriarca F, Einsele H, Spina B, et al. Long term follow-up of a 
multicenter retrospective study based on donor availability in multiple myeloma patients relapsed 
after autotransplant. Hematologica. 2015;100:B 011.] One-hundred sixty-nine consecutive patients 
underwent HLA typing at disease recurrence. The study was designed on the intent to treat principle 
and included only those patients who underwent HLA typing immediately after the relapse. Of the 
169 consecutive patients evaluated, 75 had found a donor and 72 (96%) underwent an allograft after 
reduced-intensity conditionings. Twenty-four transplants were from a HLA-identical sibling (32%) 
and 48 from an unrelated donor (68%). The two-year nonrelapse mortality was 22% in patients with 
a HLA-compatible donor (donor group) versus 1% for those without (no donor group). In the first 
report, the two-year progression-free survival and 2-year overall survival were 42% and 54%; and 
18% and 53% in the donor group and the no-donor group, respectively.[67 Patriarca F, Einsele H, 
Spina F, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a 
multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant. 
2012;18:617–626.[CrossRef], [PubMed], [Web of Science ®]] Significantly better response (p< 
 .0001) did not translate into better short-term overall survival given a higher treatment-related 
mortality in the donor group. However, in a recent update at a median follow-up of 87 months, 
presented at the meeting of the Italian Society of Hematology (Florence, 2015),[68 Patriarca F, 
Einsele H, Spina B, et al. Long term follow-up of a multicenter retrospective study based on donor 
availability in multiple myeloma patients relapsed after autotransplant. Hematologica. 2015;100:B 
011.] the 5-year progression-free survival was 21% in the donor group and 3% in the no-donor 
group (p < .001) whereas, importantly, 5-year overall survival was 40% in the donor group and 19% 
in the no-donor group (p  = .007), the difference to the advantage of the donor group being 
significantly higher in this updated report. By multivariate analysis, availability of a donor, 
chemosensitive disease at the time of the allograft and longer duration of salvage treatment were 
significant predictors for favorable progression free survival. Moreover, high-risk karyotype at 
diagnosis was significantly associated with shorter overall survival. Of note, the time interval from 
the autograft to relapse had no significant impact on clinical outcomes after the allograft. This study 
further confirms that significant differences in clinical outcomes between ‘donor groups’ and ‘no 
donor groups’ may be seen only after a number of years of follow-up. 
The current paradigm for the treatment of multiple myeloma include novel agents with potent 
antimyeloma activity, their potentially curative combination with the graft-vs-myeloma effect, 
however, has unfortunately never been explored in well-designed large prospective studies though 
their efficacy in relapsed patients after an allograft has been reported in many studies.[61 Festuccia 
M, Martino M, Ferrando F, et al. Allogeneic stem cell transplantation in multiple myeloma: 
immunotherapy and new drugs. Expert Opin Biol Ther. 2015;15:857–872.[Taylor & Francis 
Online], [Web of Science ®]] Recent reports rather convincingly further support a strong synergy 
between donor T cells and novel agents. Interestingly, Giaccone et al., in a comparative study, 
showed higher response rates to salvage therapies with bortezomib-, thalidomide-, or lenalidomide-
containing regimens in patients relapsed after an allograft, and significantly longer overall survival 
from relapse after the allograft than after a second autograft,[69 Giaccone L, Storer B, Patriarca F, 
et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for 
newly diagnosed myeloma. Blood. 2011;117:6721–6727.[CrossRef], [PubMed], [Web of Science 
®]] corroborating with results of the EBMT-NMAM2000 study.[70 Gahrton G, Iacobelli S, 
Bjorkstrand B, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs 
autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 
study. Blood. 2013;121:5055–5063.[CrossRef], [PubMed], [Web of Science ®]] Recently, 
Montefusco et al. reported on a retrospective matched-pair analysis on the use of lenalidomide as 
salvage therapy after autologous or allogeneic transplantation (personal communication). 
Lenalidomide was significantly more effective in long-term disease control in the ‘allograft group’ 
rather than in ‘autograft group’ and this translated into a significantly longer overall survival. 
Patient risk stratification should soon help optimize individual therapies. The recently Revised 
International Staging System by the International Myeloma Working Group showed that there is a 
group of newly diagnosed patients with high-risk features, including chromosomal abnormalities, 
where overall and progression-free survivals are very poor even in the era of new drugs.[71 
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple 
myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–
2869.[CrossRef], [PubMed], [Web of Science ®]] In this patient group, new effective treatments 
should be sought especially if relapse occurs early after upfront therapy. In the EBMT NMAM2000 
study, a poor prognostic impact – although weak – of del13 chromosomal abnormality seen after 
ASCT, was abrogated after tandem auto/RIC allogeneic transplantation [72 Bjorkstrand B, Iacobelli 
S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell 
transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol] 
2011;29:3016–3022.[CrossRef], [PubMed], [Web of Science ®]] and the negative prognostic 
impact of high-risk cytogenetics, appeared to be partly neutralized by graft versus myeloma in a 
recent study.[73 Kröger N, Badbaran A, Zabelina T, et al. Impact of high-risk cytogenetics and 
achievement of molecular remission on long-term freedom from disease after autologous-allogeneic 
tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 
2013;19:398–404.[CrossRef], [PubMed], [Web of Science ®]] 
All together, given that myeloma patients invariably relapse despite the recent improvement in 
overall survival, the case may be made that relapsed patients after an autograft may most benefit 
from the potentially curative effect of graft versus myeloma and its combination with potent 
antimyeloma agents especially if high-risk features are present at diagnosis.[74 Kröger N, Shimoni 
A, Schilling G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for 
patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol. 
2010;148:323–331.[CrossRef], [PubMed], [Web of Science ®]] Consolidation/maintenance 
postallogeneic transplantation using the novel agents could also improve the outcome. 
Conclusions 
Even though major therapeutic improvements have emerged to treat myeloma, all patients 
eventually relapse, perhaps with some exceptions following allogeneic transplantation and some 
new drug combinations. The treatment algorithm in the relapse setting has become confusing in 
contrast to the first line treatment where the sequence of induction followed, if eligible, by 
autologous stem cell transplantation and consolidation is well accepted. We suggest in Figure 2, a 
treatment pathway starting with different reinduction options according to initial treatment and 
followed by a transplant or no transplant approach. The role of immunotherapy with the monoclonal 
antibodies in this treatment algorithm is currently under investigation but it will definitely be an 
important part of the treatment in the near future. 
 
 
Figure 2. Treatment algorithm for relapse post autologous stem cell transplantation. 
 
Many questions remain 
At relapse, should we start treatment at biochemical or at clinical relapse? Should we incorporate in 
the clinical relapse the new criteria that are used in the first-line treatment namely a bone marrow 
plasmacytosis above 60% and/or more than one bone lesion on MRI and/or a ratio of involved over 
uninvolved free light chain above 100? 
Do we need to perform an ASCT? There are strong arguments supporting the use of a second ASCT 
if the relapse occurs at least 18 months after the first ASCT. There is also the scenario of patients 
treated initially with a tandem ASCT and who relapse sometimes many years later. Can we perform 
a third transplant and if so what is the outcome? The EBMT is currently conducting a retrospective 
registry based analysis to answer this question. 
Allogeneic transplantation is very much criticized mostly because of its NRM and morbidity. 
Toxicity has decreased substantially with the use of less myeloablative regimens but at the cost of 
an increased relapse rate. However, it remains the only potentially curable treatment of myeloma. 
Much effort will be made in the coming years to improve immunomodulation post allogeneic 
transplantation incorporating the new drugs. The checkpoint inhibitors may be an opportunity to 
increase the very potent antimyeloma allogeneic effect. For the time being, one should consider 
allogeneic transplantation in first relapse in a ‘chemosensitive’ disease. It is now very clear that it 
should not be proposed, as it was done in the past, as a ‘last ditch’ effort to control the disease. 
How to obtain a new remission at relapse? It very much depends on the efficacy and toxicity of the 
previous treatments. Retreatment with the initial combination can be done as long as there is at least 
a treatment-free interval of 6 months and the treatment was efficacious with an acceptable toxicity. 
More often, if the first line treatment was bortezomib based, the relapse treatment will be 
lenalidomide based and vice versa. If a combination of bortezomib plus lenalidomide was given and 
patients are refractory to these two drugs, we now have access to pomalidomide and carfilzomib. 
The challenge is now how to treat the quadruple refractory patients. 
Should we use a doublet or a triplet? Triplet combinations have shown to be superior both in the 
first line and the relapse setting with an increased response rate and improved PFS but less 
convincing results for OS. Triplet gives the opportunity to target more malignant clones at once and 
leaves less chance for an aggressive clone to emerge. However, at subsequent relapse, one will have 
access to less treatment option with the initial triplet use compared to the doublet and in the end OS 
may be similar. Which triplet to use? We will soon have access to at least four triplet options, three 
lenalidomide–dexamethasone based, namely plus carfilzomib, plus elotuzumab, or plus ixazomib. 
Except for the combination of lenalidomide dexamethasone plus carfilzomib which has a median 
PFS of 26 months, the two other combinations have a shorter PFS of around 20 months. The 
combination of bortezomib plus dexamethasone and panobinostat has a PFS of 11 months. For all 
four combinations, the toxicity is different as well as their potential efficacy for subpopulations 
such as high-risk cytogenetic patients. 
How long should the treatment be? If the goal is to proceed to transplantation, either autologous or 
allogeneic, at least a partial remission should be obtained. As in the first-line setting, four cycles are 
usually given but if the patient has a continuous decrease in its monoclonal peak with an acceptable 
toxicity, six cycles can be done: the better the response before transplant the better the outcome. 
Outside of the transplant setting, continuous treatment (maintenance) until the next relapse is more 
frequently undertaken but side effects may be limiting, while for some patients who experience a 
very good persistent response a treatment free period can be considered. One remaining question is 
the dose of steroids and the length of its use. Usually, the dose of steroids is progressively tapered 
and stopped after one or two years, but this is very much related to the physician’s choice. There is 
little evidence to assist this decision. 
New treatment options are emerging, mostly immune interventions such as bispecific monoclonal 
antibodies, immune checkpoint inhibitors and CAR T cells. New treatment combinations will 
emerge with a shift in the treatment paradigm with less, if any, chemotherapy and more targeted 
drugs and immunotherapy. The first goal is to prolong survival but the ultimate one is cure. 
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